Ozempic Demonstrates Superior Stroke Risk Reduction Compared to Other Diabetes Medications

Recent research highlights the potential benefits of semaglutide, commonly marketed as Ozempic, in lowering the risk of stroke among patients with type 2 diabetes. A study involving 7,899 patients treated with semaglutide compared to an equal number taking empagliflozin revealed that users of semaglutide experienced a slightly reduced overall risk of cardiovascular events, primarily driven by a significant decrease in stroke incidence.

The investigation, based on data collected from a cohort of adults aged 45 and above with comorbid conditions, employed emulated target trials to assess outcomes such as mortality, heart attack, stroke, heart failure, and irregular heartbeat. Results indicated that patients on semaglutide exhibited a modestly lower risk of death, myocardial infarction, and stroke, with the most pronounced benefit seen in stroke prevention.

Additional studies published in the >Annals of Internal Medicine> support these findings, demonstrating that semaglutide can moderately reduce the risks of death, MI, and stroke when compared to empagliflozin. The research also found that, particularly among younger patients and those with well-controlled blood sugar levels, the benefits of semaglutide were more evident.

These findings are significant for healthcare providers managing cardiovascular risks in diabetic patients, suggesting that semaglutide may be a more effective option in reducing stroke risk. The research underscores the importance of personalized treatment plans and offers new insights into the cardiovascular benefits associated with GLP-1 receptor agonists like Ozempic.

Source: https://medicalxpress.com/news/2025-06-ozempic-outperforms-diabetes-drug.html